Alphamab pre-markets Hong Kong IPO, eyes $1bn valuation
Alphamab Oncology, a Chinese biopharmaceutical company, kicked off pre-deal investor education for a potential $250m IPO on Monday after gaining approval to list from the Hong Kong Stock Exchange.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: